Early versus deferred androgen suppression therapy for patients with lymph node-positive prostate cancer after local therapy with curative intent: a systematic review

BMC Cancer

Frank Kunath¹  Bastian Keck²  Gerta Rücker⁴  Edith Motschall⁴  Bernd Wullich²  Gerd Antes¹  Joerg J Meerpohl³ 

[1] German Cochrane Centre, Institute of Medical Biometry & Medical Informatics, University Medical Centre Freiburg, Freiburg, Germany

[2] Department of Urology, University Clinic Erlangen, Krankenhausstraße 12, 91054, Erlangen, Germany

[3] Pediatric Hematology and Oncology, Centre for Pediatrics & Adolescent Medicine, University Medical Centre Freiburg, Freiburg, Germany

[4] Institute of Medical Biometry and Medical Informatics, University Medical Centre Freiburg, Freiburg, Germany

关键词: Meta-analysis;    Systematic review;    Androgen suppression therapy;    Lymph node excision;    Lymphatic metastasis;    Prostatic neoplasms;   

Others  :  1079859
DOI  :  10.1186/1471-2407-13-131

 received in 2012-06-01, accepted in 2013-03-12,  发布年份 2013

【 摘 要 】

Background

There is currently no consensus regarding the optimal timing for androgen suppression therapy in patients with prostate cancer that have undergone local therapy with curative intent but are proven to have node-positive disease without signs of distant metastases at the time of local therapy. The objective of this systematic review was to determine the benefits and harms of early (at the time of local therapy) versus deferred (at the time of clinical disease progression) androgen suppression therapy for patients with node-positive prostate cancer after local therapy.

Methods

The protocol was registered prospectively (CRD42011001221; http://www.crd.york.ac.uk/PROSPERO webcite). We searched the MEDLINE, EMBASE, and CENTRAL databases, as well as reference lists, the abstracts of three major conferences, and three trial registers, to identify randomized controlled trials (search update 04/08/2012). Two authors independently screened the identified articles, assessed trial quality, and extracted data.

Results

Four studies including 398 patients were identified for inclusion. Early androgen suppression therapy lead to a significant decrease in overall mortality (HR 0.62, 95% CI 0.46-0.84), cancer-specific mortality (HR 0.34, 95% CI 0.18-0.64), and clinical progression at 3 or 9 years (RR 0.29, 95% CI 0.16-0.52 at 3 years and RR 0.49, 95% CI 0.36-0.67 at 9 years). One study showed an increase of adverse effects with early androgen suppression therapy. All trials had substantial methodological limitations.

Conclusions

The data available suggest an improvement in survival and delayed disease progression but increased adverse events for patients with node-positive prostate cancer after local therapy treated with early androgen suppression therapy versus deferred androgen suppression therapy. However, quality of data is low. Randomized controlled trials with blinding of outcome assessment, planned to determine the timing of androgen suppression therapy in node-positive prostate cancer using modern diagnostic imaging modalities, biochemical testing, and standardized follow-up schedules should be conducted to confirm these findings.

【 授权许可】

   
2013 Kunath et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
• [2]Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, Pan L, Anderson RN, Fulton JE, Kohler BA: Annual Report to the Nation on the status of cancer, 1975–2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012, 118(9):2338-2366.
• [3]Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011, 59(1):61-71.
• [4]Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002, 167(2 Pt 2):948-951. discussion 952
• [5]Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011, 59(4):572-583.
• [6]Parmar MK, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17(24):2815-2834.
• [7]Williamson PR, Smith CT, Hutton JL, Marson AG: Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002, 21(22):3337-3351.
• [8]Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16. BioMed Central Full Text
• [9]Lawton CA, Winter K, Grignon D, Pilepich MV: Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85–31. J Clin Oncol 2005, 23(4):800-807.
• [10]Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD: Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85–31). Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1997, 38(5):931-939.
• [11]Granfors T, Modig H, Damber J-E, Tomic R: Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 2006, 176(2):544-547.
• [12]Granfors T, Modig H, Damber JE, Tomic R: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998, 159(6):2030-2034.
• [13]Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341(24):1781-1788.
• [14]Messing EM, Manola J, Sarosdy M, Wilding G, Crawford D, Kiernan M, Trump D: Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: At 10 years results of EST3886. J Clin Oncol 2004, 22(14s):4570.
• [15]Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di’SantAgnese PA, Trump D, Eastern Cooperative Oncology Group study EST: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006, 7(6):472-479.
• [16]Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM: Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. Urology 2004, 63(5):928-933.
• [17]Iversen P, Wirth MP, See WA, McLeod DG, Morris T, Armstrong J: The influence of nodal status on progression outcomes in patients with prostate cancer: Data from Early Prostate Cancer program at 7.4 years. J Clin Oncol 2006, 24(18S):abstract 4628.
• [18]Heidenreich A, Bolla M, Joniau S, Mason MD, Matveev V, Mottet N, Schmid HP, van der Kwast TH, Wiegel T, Zattoni F: Guidelines on Prostate Cancer [online]. European Association of Urology 2010. http://www.uroweb.org/guidelines/copyright-and-republication/how-to-reference-the-eau-guidelines/ webcite (downloaded on 13/03/2012)
• [19]Anscher MS, Prosnitz LR: Prognostic significance of extent of nodal involvement in stage D1 prostate cancer treated with radiotherapy. Urology 1992, 39(1):39-43.
• [20]Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F: Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N + patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009, 55(2):261-270.
• [21]Zincke H, Utz DC, Thule PM, Taylor WF: Treatment options for patients with stage D1 (T0–3, N1–2, M0) adenocarcinoma of prostate. Urology 1987, 30(4):307-315.
• [22]Gjertson CK, Asher KP, Sclar JD, Goluboff ET, Olsson CA, Benson MC, McKiernan JM: Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology 2007, 70(4):723-727.
• [23]Myers RP, Zincke H, Fleming TR, Farrow GM, Furlow WL, Utz DC: Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer. J Urol 1983, 130(1):99-101.
• [24]Kramolowsky EV: The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 1988, 139(6):1242-1244.
• [25]Feyaerts A, Stainier L, Nollevaux MC, De Groote P, Lorge F, Opsomer R, Wese FX, Cosyns JP, Van Cangh P: [Complete radical prostatectomy and positive lymph nodes (stages pT1 to 4, N1 to 3, M0, D1)]. Acta Urol Belg 1998, 66(1):1-6.
• [26]Spiess PE, Lee AK, Busby JE, Jordan JJ, Hernandez M, Burt K, Troncoso P, Merriman KW, Pisters LL: Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome? BJU Int 2007, 99(2):321-325.
• [27]de Kernion JB, Neuwirth H, Stein A, Dorey F, Stenzl A, Hannah J, Blyth B: Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J Urol 1990, 144(3):700-703.
• [28]Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K: Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 2009, 27(1):100-105.
• [29]Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, Frank I, Blute ML: Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007, 178(3 Pt 1):864-870. discussion 870–861
• [30]Cheng CW, Bergstralh EJ, Zincke H: Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer 1993, 71(3 Suppl):996-1004.
• [31]Myers RP, Larson-Keller JJ, Bergstralh EJ, Zincke H, Oesterling JE, Lieber MM: Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup. J Urol 1992, 147(3 Pt 2):910-915.
• [32]Zincke H: Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate. Significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology 1989, 33(5 Suppl):27-36.
• [33]Seay TM, Blute ML, Zincke H: Long-term outcome in patients with pTxN + adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998, 159(2):357-364.
• [34]Taylor LG, Canfield SE, Du XL: Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009, 115(11):2388-2399.
• [35]Wirth M, Tyrrell C, Delaere K, Sanchez-Chapado M, Ramon J, Wallace DM, Hetherington J, Pina F, Heyns CF, Navani S: Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years’ follow-up. Prostate Cancer Prostatic Dis 2007, 10(1):87-93.
• [36]van Andel G, Kurth KH: The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol 2003, 44(2):209-214.
• [37]Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR: Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85–31. J Clin Oncol 2009, 27(1):92-99.
• [38]Wiegand LR, Hernandez M, Pisters LL, Spiess PE: Surgical management of lymph-node-positive prostate cancer: improves symptomatic control. BJU Int 2011, 107(8):1238-1242.
• [39]Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001, 58(6):843-848.
• [40]Miyamae K, Kitani K, Miyamoto K, Hamada S, Kawano T, Maehara A, Otsuka Y, Otsuka T, Hamada Y: [Evaluation of immediate androgen deprivation adjuvant therapy in patients with lymph node positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy]. Nippon Hinyokika Gakkai Zasshi 2009, 100(5):570-575.